AstraZeneca PLC (AZN) Gains After Successful Saphnelo Trial

TheFly reported connected January 6 that Barclays expert James Gordon accrued the terms people connected AZN to 16,500 GBp from 14,000 GBp. The steadfast maintained an Overweight standing connected the shares.

On the aforesaid day, AstraZeneca announced statistically important results from its Phase III TULIP‑SC proceedings of Saphnelo (anifrolumab) successful systemic lupus erythematosus (SLE). Subcutaneous self-administration of Saphnelo led to a clinically important simplification successful illness enactment astatine Week 52, with 56.2% of patients showing betterment arsenic opposed to 37.1% successful the placebo group. These results enactment saphnelo’s imaginable arsenic an SLE therapy.

AstraZeneca PLC (NASDAQ:AZN) is simply a planetary biopharmaceutical institution advancing crab attraction done a robust late-stage oncology pipeline, innovative targeted therapies, and immuno-oncology treatments, aiming to amended diligent outcomes crossed aggregate tumor types worldwide.

While we admit the imaginable of AZN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.